Evidence Details

Allele C*15:02
Disease ankylosing spondylitis
Publication Wang. MHC associations of ankylosing spondylitis in East Asians are complex and involve non-HLA-B27 HLA contributions. 32272966.
Needs Review False
Status In Progress
HCI Evidence ID E000002
Added 2025-08-26
Back to Curation

Data

Edit
Field Status Value Notes
Genome-Wide Association Study Provided False
Zygosity Provided Monoallelic (heterozygous)
Phase Confirmed Provided False
Typing Method Provided Imputation "genotyped with the customised SNP array (Illumina Immunochip)", "We conducted a 2-step imputation. We densely imputed SNPs across the MHC using the Michigan Imputation Server [8] and the 1000 Genomes Phase 3 reference dataset [...] Using this SNP data and the Han Chinese reference panel (N = 9869), the programme SNP2HLA was used to impute the classic HLA alleles..."
Demographics Provided
  • East Asian
"A total of 1637 Chinese, Taiwanese, and Korean AS cases meeting the modified New York Criteria for AS [5] as confirmed by qualified rheumatologists, and 1589 ethnically matched controls..."
p-value Provided 6.78e-23
Multiple Testing Correction Not Provided
Odds Ratio Provided 7.62
Relative Risk Not Provided
Beta Coefficient Not Provided
Confidence Interval Not Provided
Cohort Size Provided 2994 1482 cases and 1512 controls
Additional Phenotypes Not Provided
Significant Association Provided True
Protective Provided False
Needs Review Provided False

Score

Step Category Points
Step 1A: Allele or Haplotype Allele +0.0
Haplotype +2.0
Step 1B: Allele Resolution 1-field +0.0
2-field +1.0
3-field, G-group, P-group +2.0
4-field +3.0
Step 1C: Zygosity Monoallelic (heterozygous) +0.0
Biallelic (homozygous) +0.5
Step 1D: Phase Phase confirmed +0.5
Step 2: Typing Method Tagging / Tag SNPs / Microarrays +0.0
Serological +1.0
Imputation +2.0
Molecular genotyping (low and high resolution) / Whole exome sequencing / RNA sequencing +3.0
Sanger-sequencing-based typing / Whole gene sequencing +4.0
Whole genome sequencing / Panel-based next generation sequencing (> 50x coverage) / Long-read sequencing +5.0
Step 3A: Statistics (p-value)
GWAS
Non-GWAS
0.0001 ≤ p-value < ∞
0.05 ≤ p-value < ∞
+0.0
5E-8 ≤ p-value < 0.0001
0.01 ≤ p-value < 0.05
+0.5
1E-11 ≤ p-value < 5E-8
0.0005 ≤ p-value < 0.01
+1.0
1E-14 ≤ p-value < 1E-11
0.0001 ≤ p-value < 0.0005
+1.5
-∞ < p-value < 1E-14
-∞ < p-value < 0.0001
+2.0
Step 3B: Multiple Testing Correction Overall correction for multiple testing +1.0
2-step p-value correction +2.0
Step 3C: Statistics (Effect Size)*
  • 2.0 ≤ OR/RR < ∞
  • -∞ < OR/RR ≤ 0.5
  • 0.5 ≤ Beta < ∞
  • -∞ < Beta ≤ -0.5
+1.0
CI does not cross 1 (OR/RR) or 0 (beta) +1.0
Step 4: Cohort Size
GWAS
Non-GWAS
-∞ < size < 1000
-∞ < size < 50
+0.0
1000 ≤ size ≤ 2499
50 ≤ size ≤ 99
+1.0
2500 ≤ size ≤ 4999
100 ≤ size ≤ 249
+2.0
5000 ≤ size ≤ 9999
250 ≤ size ≤ 499
+3.0
10000 ≤ size < ∞
500 ≤ size < ∞
+4.0
Step 5: Additional Phenotypes Has specific disease-related phenotype +2.0
Only disease tested +0.0
Total Before Multipliers 10.0
Step 6A: Weighing Association (multiplier) Significant association with disease ×1.0
No significant association ×0.0
Step 6B: Low Field Resolution (multiplier) 1-field resolution ×0.5
> 1-field resolution ×1.0
Total 10.0

*OR (Odds Ratio), RR (Relative Risk), CI (Confidence Interval).

*Step 3C can award points for both categories (OR/RR/Beta and CI), granting a total of up to 2.